4 completed, 2 terminated, 1 withdrawn. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 2, Withdrawn 1 |
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow Interferon-beta: new trials by email Literature Review of Interferon-beta trials Research Report on Interferon-beta
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Biogen | 2021-06-30 | 2023-06-01 | |
| Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7 | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 8 | 2015-11-06 | 2022-03-22 |
| Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma Aldesleukin, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Recurrent Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 4 | 2013-02-01 | 2017-04-19 |
| REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients Interferon-beta and human leukocyte Interferon-α - Multiple Sclerosis | Phase 2 | Completed | Melinda Magyari | 10 | 2010-07-01 | 2012-11-30 |
| Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II Interferon Beta - Acute Lung Injury, Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Completed | Faron Pharmaceuticals Ltd | 37 | 2009-02-01 | 2015-05-27 |
| A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) Cladribine, Placebo, Interferon-beta (IFN-beta) - Multiple Sclerosis | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 172 | 2006-11-30 | 2020-10-12 |
| Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma recombinant interferon beta - Stage IV Melanoma, Recurrent Melanoma | Phase 2 | Completed | Case Comprehensive Cancer Center | 21 | 2004-04-01 | 2015-10-02 |
Carcinoma, Merkel Cell (2) · Multiple Sclerosis (2) · Acute Lung Injury (1) · Melanoma (1) · Respiratory Distress Syndrome (1) · Uveal Melanoma (1)
Fred Hutchinson Cancer Center (2) · Biogen (1) · Case Comprehensive Cancer Center (1) · EMD Serono Research & Development Institute, Inc. (1) · Faron Pharmaceuticals Ltd (1) · Melinda Magyari (1)
United States (4) · Italy (1) · Russia (1) · Spain (1) · United Kingdom (1)
Aude Chapuis (2) · Alan Davidson, MD (1) · Alexander Binning, MD (1) · Ernest C. Borden, MD (1) · Geoff Bellingan, MD (1) · Martin Kuper, MD (1) · Martin Stotz, MD (1) · Mathew Wise, MD (1) · Melinda Magyari, M.D. (1) · Richard Beale, MD (1) · Timothy Walsh, MD (1)
PMID 24503265, PMID 25877635, PMID 30027104, PMID 32447743
P30CA015704 (2), 2009 (1), 2019 (1), K24CA139052 (1), P30CA043703 (1), R01CA176841 (1)